Share This

Public company info - Nanjing Sinolife United Co. Ltd. - H Shares , 03332.HK
Input the stock code or the company name     Search  
 
 Profile   Information   Data   Financial Ratios   Profit Loss   Cash Flow   Balance   Earnings   Dividend 

Nanjing Sinolife United Co. Ltd. - H Shares, 03332.HK - Company Profile
Chairman Gui Pinghu
Share Issued (share) 272,000,000
Par Currency Renminbi
Par Value 0.1
Industry Health Products
Corporate Profile Business Summary: The Group is principally engaged in the manufacture and sale of nutritional supplements and the trading of packaged health food products in the PRC, Australia and New Zealand. Performance for the year: Revenue decreased by approximately 28.8% to RMB322.6 million (2018: RMB453.2 million). Gross profit decreased by approximately 37.0% to RMB156.8 million (2018: RMB249.0 million). Loss for the Year was approximately RMB194.7 million (2018: Loss of RMB112.8 million). Loss per share was RMB20.57 cents (2018: Loss per share RMB11.92 cents). Business Review In 2019, to further implement the Group’s development strategy, the Group made great efforts into the development of products under the maternity and child series, continued to diversify its various sales channels including distributors, TV shopping platforms and e-commerce platforms, and strengthened the marketing of the Good Health brand series products. The sales revenue for the Year decreased as compared to that of 2018 due to the reduced sales revenue of original retail shops under the Zhongsheng brand and online call centres as a result of the Group’s adjustment o f sales channels. The revenue o f the Group decreased from approximately RMB453.2 million in 2018 to approximately RMB322.6 million for the Year, representing a decrease of approximately 28.8%. The Group recorded a loss of approximately RMB194.7 million, as compared to a loss of approximately RMB112.8 million in 2018. During the Year, the Group continued to adopt the strategies of focusing on the Good Health brand and sales promotion through distributors, TV shopping and e-commerce channels, so as to achieve increasingly higher brand recognition of Good Health brand in the target markets. The Group carried out continuous brand building and promotion mainly through combination of distributors, TV shopping platforms, chain pharmacies and travel channels, and at the same time by opening flagship stores on domestic major e-commerce platforms. During the Year, in order to enhance the market competitiveness of its products and meet the evolving consumer demands, the Group has adopted a market-oriented strategy for research and product development to further strengthen the development of new products. During the Year, the Group has launched a total of 25 new products, including 2 Hejian series products, 20 Good Health series products and 3 Living Nature series products. The new products mainly comprise probiotic solid beverage, green-lipped mussel, organic fucoidan capsule and DHA & PS soft capsule. For the PRC’s market, the Group has made great effort to develop domestic distributors, TV shopping platforms and e-commerce platforms during the Year. In terms of TV shopping platforms, the Group has built cooperation with a number of platforms including yougou.com, hao24.com, best1.com, jiajiamall, CNRmall, happigo.com, ocj.com.cn and Global Home Shopping to sell general trade and cross-border trade products. In terms of e-commerce platforms, the Group continued to cooperate with e-commerce platforms such as Tmall International, JD.com, suning.com, xiaohongshu.com, pinduoduo.com and Health Post. The Group’s overseas diversified sales platforms mainly include international distribution network broadly distributed in countries including the United Kingdom, Germany, Singapore, Vietnam and Thailand, and local large chain pharmacies, health goods supermarkets and tourist souvenir shops in New Zealand and Australia. Prospects: In 2019, in order to establish a healthy environment for the development of the health product industry, the Chinese government regulators further strengthened the supervision and rectification measures to ensure that the health product market will become more and more standardised. When people take the initiative to boost healthy immunity as a rigid demand in life, the consumption of health products will become more normalised, and the management of product research, development and product application will also become more refined, thereby guiding consumers to improve their level of health in a more scientific way. For enterprises in the industry, high-quality products, standardised production and brand credibility will be the most important core competitiveness. The Good Health brand exactly meets the above requirements. The outbreak of the novel coronavirus epidemic in early 2020 has caused material impact on the PRC’s economic operation and the living of the public. The epidemic also affected the Company’s daily operation to a certain extent, especially in the product distribution and logistics. Recently, with the gradual control and mitigation of the PRC’s epidemic, logistics and distribution have basically resumed to normal. The Company has evaluated the epidemic with due care and believes that it will not bring material impact on the Company’s daily operation and cash flow. The fight against the epidemic also arouses the public to reflect on the importance of health and immunity. After the SARS epidemic, the health product industry ushered in a wave of growth since 2003. With the subsequent vigorous efforts invested by the PRC into the big health industry and the improvement of the living standards of the public, the health product industry has maintained growth year by year. According to the data from thirdparty statistical agencies, the global health product market reached US$266.7 billion in 2019, and the PRC has become the world’s second largest health product market with its market share of up to 21.8% and a volume of approximately US$58 billion which demonstrated yearby-year growth. In 2020, the Company will continue to implement its established development strategy and focus on the Good Health brand. In particular, it will increase investment in research and development, market promotion, and channel construction of products under the maternity and child series to increase the Company’s results in 2020.

Information from the financial statements of listed companies

Mobile | Full
Forum rule | About Us | Contact Info | Terms & Conditions | Privacy Statment | Disclaimer | Site Map
Copyright (C) 2024Suntek Computer Systems Limited. All rights reserved
Disclaimer : In the preparation of this website, 88iv endeavours to offer the most current, correct and clearly expressed information to the public. Nevertheless, inadvertent errors in information and in software may occur. In particular but without limiting anything here, 88iv disclaims any responsibility and accepts no liability (whether in tort, contract or otherwise) for any direct or indirect loss or damage arising from any inaccuracies, omissions or typographical errors that may be contained in this website. 88iv also does not warrant the accuracy, completeness, timeliness or fitness for purpose of the information contained in this website.